Novocure sought to develop a new way to treat solid tumor cancers.

In 2000, Yoram Palti, our founder and professor emeritus of physiology and biophysics at the Technion — Israel Institute of Technology, sought to leverage his expertise in biophysics to develop a new way to treat solid tumor cancers that would destroy tumor cells while sparing healthy tissue and avoiding many of the life-altering side effects of existing cancer therapies.

He set up a laboratory in his basement to explore the potential of electric fields as a treatment for solid tumors.

Professor Palti founded Novocure to provide patients with a new cancer treatment based on his hypothesis, since proven, that low-intensity, alternating electric fields, when applied at specific frequencies, can disrupt cancer cell division and cause cancer cell death. This innovative treatment,   Tumor Treating Fields, or TTFields, is a completely different approach to cancer therapy.

Nobody understood what I was doing,” Professor Palti said on his early development of TTFields therapy.

More Than
950
global treatment centers
2
approved indications
5
indications in our clinical pipeline

Novocure corporate timeline

Since our founding in 2000, we have reached many key milestones. Click through to see some of our proudest moments.

2017

Phase 3 pivotal trial in non-small cell lung cancer begins

More

2016

U.S. FDA approves second generation Optune System

More

2016

Phase 3 pivotal trial in brain metastases begins

More

2015

U.S. FDA approves Optune for newly diagnosed glioblastoma

More

2011

U.S. FDA approves Optune for recurrent glioblastoma

More

2009

Phase 3 pivotal EF-14 trial opens

More

2006

Phase 3 pivotal EF-11 trial opens

More

2004

First peer-reviewed article published

More

2004

Glioblastoma pilot trials open

More

2002

Research center established

More

2000

Professor Yoram Palti, MD, PhD, founds Novocure

More

Palti’s initial research from his basement laboratory has evolved to become an international oncology company with more than 450 employees and operations in the U.S., Europe and Asia.

We launched Optune® – our TTFields delivery system for glioblastoma (GBM) – in the United States for the treatment of recurrent glioblastoma in 2011. In October 2015, we received U.S. Food and Drug Administration (FDA) approval to market and sell Optune for the treatment of adult patients with newly diagnosed GBM in combination with temozolomide.  We actively market for that indication in the United States, Germany and Switzerland.

The science of TTFields has the potential to extend beyond GBM. We have five ongoing or completed phase 2 pilot trials for brain metastases, non-small cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. We presented our phase 2 pilot data in pancreatic and ovarian cancers at our research and development day on Dec. 12, 2016. In 2016, we began our phase 3 pivotal trial in brain metastases originating from NSCLC. In 2017, we started our phase 3 pivotal trial in NSCLC. Internationally, more than 20 institutions are studying the effects of TTFields in cancer treatment.

Our company began with a patient-forward approach that continues to drive our mission today. With more than 15 years of research and many significant milestones, we have established ourselves as an innovator in oncology dedicated to improving the lives of cancer patients.

Founded in
2000
450+
employees

leadership at Novocure

Our leaders have extensive experience across the oncology, biotechnology and medical device industries.

Our Leadership
Picture

2000 Novocure research center opens